Life Sciences Tools and Services
Company Overview of MolecularMD Corp.
MolecularMD Corp. develops and commercializes specialty molecular diagnostics for oncology applications. The company provides molecular diagnostics products and services to pharmaceutical and biotech drug developers. Its products and services are used to select, monitor, and manage response for patients treated with molecularly-targeted cancer therapies in alignment with clinical development and regulatory approval strategies. The company also offers clinical testing services, such as assay development, customized reporting, trial site support, investigator education, laboratory certification, test capacity, data management, and clinical trial IUO kits. In addition, it creates oncology molec...
1341 SW Custer Drive
Portland, OR 97219
Founded in 2005
Key Executives for MolecularMD Corp.
Chief Executive Officer, President and Director
Scientific Co-Founder and Scientific Advisor
Chief Medical Officer, Executive Vice President, Laboratory Director and Director
Chief Technology Officer and Executive Vice President
Compensation as of Fiscal Year 2016.
MolecularMD Corp. Key Developments
Illumina Enters into Agreement with MolecularMD for Development of Companion Diagnostics
Jun 27 16
Illumina has entered into an agreement with Molecular MD that establishes a framework for potential collaborations with respect to the development and commercialization of sequencing-based companion diagnostics. This agreement is designed to deliver the combined power of Illumina's NGS technologies with MolecularMD's ability to tailor a complete clinical development solution including regulatory planning, IDE validations and centralized testing and data management for global patient enrollment and disease monitoring.
Molecularmd Enters into Collaboration Agreement with Illumina for Drug-Diagnostic Co-Development with Biopharma Drug Programs
Jun 27 16
MolecularMD Corporation announced that it has entered into an agreement with Illumina Inc. that establishes a framework for potential collaborations with respect to the development and commercialization of sequencing-based companion diagnostics in support of biopharma drug development program(s). The agreement dovetails MolecularMD's companion diagnostic development and FDA submission experience with Illumina's NGS technology.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 5, 2016
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries